Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

“…Despite the different dosing schedules reported in CORRELATE, regorafenib effectiveness was consistent with previous reports [2,7,8]. The results of ReDOS support this flexible dosing approach, showing that a dose-escalation schedule can be used in clinical practice [16]. Exploratory analyses of effectiveness in CORRE-LATE showed that OS and PFS were similar for patients with left-and right-sided tumours, suggesting that although tumour sidedness has been found to be prognostic, and even predictive, in the first-line setting [17,18], this effect may not be observed in later lines.…”

“…Physicians previously described starting regorafenib at doses less than 160 mg and increasing the dose as tolerated [14,15]. A recent randomised phase II trial (ReDOS) reported that weekly dose escalation from 80 mg to 160 mg during the first cycle allowed more patients to complete two cycles of treatment and initiate a third compared with starting at the approved 160-mg dose [16]. In CORRELATE, patients starting regorafenib at 80 mg daily tended to be older, were more likely to be Asian and had a worse performance status, a lower body weight and a lower body mass index than those starting at 160 mg or 120 mg daily.…”

Treatment Outcomes in Patients Receiving Regorafenib for Metastatic Colon Cancer

“…The survival outcomes were not significantly different. 9 While the small sample size limits robust statistical inference, our data concur with the latest evidence. As the slow dose escalation approach appears to result in better tolerability and safety, we expect it to gain popularity in the near future.…”

Second-line treatment of hepatocellular carcinoma: from theory to practical issues

“…Более чем в половине случаев (54%) требовалось снижение дозы препарата из-за токсичности, только в 10% случаев терапия была прекращена. Не имея в своем арсенале значимых предикторов токсичности мультикиназных ингибиторов, онкологи в ряде случаев, ориентируясь на результаты исследования ReDOS [17], при химиорефрактерном колоректальном раке могут начинать лечение регорафенибом с меньшей суточной дозы (120-80 мг) и при хорошей переносимости переходить на стандартный режим дозирования.…”